ClinicalTrials.gg
RecruitingNCT06987539THYMEUpdated Oct 23, 2026

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

A Phase 2 interventional study of Inebilizumab in Generalized Myasthenia Gravis, sponsored by Amgen. Recruiting at 14 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 23, 2026First sites in Italy and United Kingdom7 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.

Planned enrollment
85th of 108
15 · median 56
Started
2026
with 16 others
Phase 2
26 of 144
5 open now
Primary completion
2030-03
later than 60 of 72 live
Registered
123rd of 144
by date
Lead sponsor
2 of 144
Amgen

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 85th largest by planned enrollment of the 108 interventional ones that give a count, is one of 17 that started in 2026, is one of 26 in phase 2, reaches primary completion later than 60 of the 72 other live ones, and was the 123rd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • Generalized Myasthenia Gravis
  • Inebilizumab
  • AMG 335
  • Uplizna
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant's legally authorized representative has provided when the participant is legally too young to provide informed consent and the participant has provided written assent based on local regulations and/or guidelines before any study-specific activities/procedures being initiated.
  • Age ≥ 2 to \< 18 years of age on the day of enrollment.
  • Diagnosis of gMG defined as:

    • Positive serologic test for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody (Ab) titers as confirmed at screening (1 retest allowed), and
    • At least 1 of the following:

      • History of abnormal neuromuscular transmission test results demonstrated by single-fiber electromyography or repetitive nerve stimulation; or
      • History of positive anticholinesterase test (eg, edrophonium chloride test); or
      • Participant demonstrated improvement in gMG signs on oral cholinesterase inhibitors, as assessed by the treating physician; or
      • Clinical syndrome consistent with a diagnosis of gMG, and not otherwise explained by another condition.
  • Myasthenia Gravis Foundation of America Clinical Classification Class II, III, or IV at the time of screening.
  • Participants must be on:

    • only, with no dose increase within 4 weeks prior to screening, or
    • One allowed non-steroidal therapies (IST), (azathioprine, mycophenolate mofetil, or mycophenolic acid) with continuous use for at least 6 months prior to screening and no dose increase within 4 months prior to screening, or
    • Combination of (1) corticosteroids with no dose increase within 4 weeks prior to screening and (2) one allowed non-steroidal IST with continuous use for at least 6 months prior to screening and no dose increase within 4 months prior to screening.

Note:

The maximum allowed dose of prednisone at the time of enrollment will be 40 mg/day or 80 mg every other day, or equivalent corticosteroid dose.

Tacrolimus is allowed in Japan only, with continued use for ≥ 6 months prior to screening and no dose increase within 4 months prior to screening.

  • Participants may enter the study on a stable dose of acetylcholinesterase inhibitors (pyridostigmine dose). The acetylcholinesterase inhibitor dose must have been stable for at least 2 weeks prior to enrollment.
  • Vital signs and laboratory parameters within the normal ranges at screening, or, if outside normal ranges, deemed not by the investigator.

Exclusion criteria

Exclusion Criteria

  • Employees of the Sponsor, contract research organization (CRO), site staff, and their family members.
  • Thymectomy within 12 months prior to baseline (Day 1) visit or planned thymectomy during the duration of the treatment period.
  • Unresected thymoma- Participants with benign thymoma resected > 12 months prior to screening may enroll.
  • History of recurrent significant infections.
  • Known immunodeficiency disorder, including current infection or positive test for (HIV).
  • Positive test for chronic infection at screening.
  • History of untreated infection, or positive antibody test for hepatitis C virus (HCV).
  • Active tuberculosis (TB); latent TB with no documented history of adequate treatment per local standard of care; or a positive QuantiFERON®-TB test at screening, unless treatment for TB was completed per local guidelines.
  • History of progressive multifocal leukoencephalopathy.
  • Participants diagnosed with congenital myasthenic syndromes.
  • Receipt of any biologic B-cell-depleting therapy (eg, rituximab, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab) or any experimental B-cell-depleting agent in the 6 months prior to screening.
  • Receipt of any other monoclonal antibody (mAb) or large molecule biologic, including but not limited to FcRn inhibitors, anti-TNF mAbs, anti-janus kinase (JAK) Stat mAbs, and complement inhibitors within 6 months prior to screening.
  • Receipt of the following medications or treatments at any time prior to enrollment: alemtuzumab, total lymphoid irradiation, bone marrow transplant, T-cell vaccination therapy, natalizumab.
  • Participants who are pregnant or breastfeeding or planning to get pregnant.
  • Receipt of intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) within 4 weeks prior to enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Inebilizumab

    Inebilizumab will be administered intravenously (IV).

    Drug: Inebilizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Inebilizumab

    Time frame: Up to Week 52

  2. Area Under the Concentration-time Curve (AUC) of Inebilizumab

    Time frame: Up to Week 52

  3. Half-life (t1/2) of Inebilizumab

    Time frame: Up to Week 52

  4. Clearance (CL) of Inebilizumab

    Time frame: Up to Week 52

  5. Volume of Distribution at Steady State (Vss) of Inebilizumab

    Time frame: Up to Week 52

  6. Change from Baseline in Cluster of Differentiation 20 (CD20)+ B-cell Counts

    Time frame: Baseline and Week 78

  7. Number of Participants Experiencing Treatment-emergent Adverse Events

    Time frame: Up to Week 78

  8. Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters

    Time frame: Up to Week 78

  9. Number of Participants Experiencing Clinically Significant Changes in Vital Signs

    Time frame: Up to Week 78

Secondary outcomes

  1. Change from Baseline in Quantitative Myasthenia Gravis (QMG) Score

    Time frame: Baseline and Week 78

  2. Change from Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score

    Time frame: Baseline and Week 78

  3. Change from Baseline in Euro Quality of Life-5 Dimension Youth (EQ-5D-Y) Score

    Time frame: Baseline and Week 78

  4. Change from Baseline in Neurological Quality of Life (Neuro-QoL) Pediatric Fatigue Score

    Time frame: Baseline and Week 78

  5. Number of Participants with Anti-drug Antibodies (ADAs) Present

    Time frame: Up to Week 78

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2030, 43 months after the start.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 23, 2025
StartActual
Jul 21, 2026
Primary completionEst.
Mar 13, 2030
CompletionEst.
Mar 13, 2030
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 2 sites removed — first sites in Italy and United Kingdom
Show 7 added (2 United States, 1 Argentina, 1 Brazil, 1 France, 1 Italy, 1 United Kingdom)
  • Seattle Childrens Hospital · Seattle, United States
  • Hospital Italiano de Buenos Aires · CABA, Argentina
  • Instituto da Crianca - Hospital das Clinicas Fmusp · São Paulo, Brazil
  • Hopital Armand Trousseau · Le Kremlin-Bicêtre, France
  • Azienda Ospedaliera Universitaria Meyer · Florence, Italy
  • John Radcliffe Hospital · Oxford, United Kingdom
  • Ann and Robert H Lurie Childrens Hospital of Chicago · Chicago, United States
Show 2 removed
  • Hospital Italiano de Buenos Aires · Ciudad Autonoma de Buenos Aires, Argentina
  • Hopital Armand Trousseau · Paris, France
across 2 updates, Oct 5, 2026 – Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    1 site added
    Show site
    • Ann and Robert H Lurie Childrens Hospital of Chicago · Chicago, United States
    + 1 other change: verification date
  2. Oct 5, 2026
    6 sites added, 2 sites removed — first sites in Italy and United Kingdom
    Show 6 added (1 United States, 1 Argentina, 1 Brazil, 1 France, 1 Italy, 1 United Kingdom)
    • Seattle Childrens Hospital · Seattle, United States
    • Hospital Italiano de Buenos Aires · CABA, Argentina
    • Instituto da Crianca - Hospital das Clinicas Fmusp · São Paulo, Brazil
    • Hopital Armand Trousseau · Le Kremlin-Bicêtre, France
    • Azienda Ospedaliera Universitaria Meyer · Florence, Italy
    • John Radcliffe Hospital · Oxford, United Kingdom
    Show 2 removed
    • Hospital Italiano de Buenos Aires · Ciudad Autonoma de Buenos Aires, Argentina
    • Hopital Armand Trousseau · Paris, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06987539
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Jul 21, 2026
Primary completion
Mar 13, 2030 (estimated)
Completion
Mar 13, 2030 (estimated)
Last update
Oct 23, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion